In back-to-back failures, Anthera’s CF drug Sollpura falls short in PhIII, shares crater (again)
Six weeks after Anthera $ANTH suffered a failed Phase III study for its lupus drug blisibimod, the small biotech was forced to concede that its …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
